The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants
Open accessAbstract
The need for new adjuvants is absolutely cardinal to the development of new vaccines and to further optimizing current immunization approaches. However, only a few classes of adjuvants are presently incorporated in vaccines approved for human use. Recent advances in the discovery and delivery of TLR agonists as vaccine adjuvants have begun to open up a new toolbox for vaccinologists. At the forefront of this movement is the use of synthetic small molecule TLR7/8 agonist–based adjuvants. In this review, we emphasize the importance of vaccine formulation science in driving recent developments in TLR7/8 adjuvanticity, summarize some of the most current and notable studies in this field, and discuss desirable attributes of next generation TLR7/8 adjuvants for use in enhancing vaccine responses in vulnerable populations, such as the very young. Finally, we explore advances that may further edge the development of TLR7/8 adjuvant–based vaccine formulations toward clinical human evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Liu, L., Johnson, H. L., Cousens, S., Perin, J., Scott, S., Lawn, J. E., Rudan, I., Campbell, H., Cibulskis, R., Li, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60560-1 · Cited by 3,934
Levy, O., Zarember, K. A., Roy, R. M., Cywes, C., Godowski, P. J., & Wessels, M. R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4627 · Cited by 375
Nabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271
Recent progress in adjuvant discovery for peptide-based subunit vaccines
Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M., & Toth, I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27332 · Cited by 239 · cited 1×
“These are usually produced as solid block particles ranging from 50 to 500 nm in size, withAgs entrappedor adsorbedonthe surfaceof theparticles (53).”
BackgroundJackson, S., Lentino, J., Kopp, J., Murray, L., Ellison, W., Rhee, M., Shockey, G., Akella, L., Erby, K., Heyward, W. L., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.038 · Cited by 197
Van Hoeven, N., Fox, C. B., Granger, B., Evers, T., Joshi, S. W., Nana, G. I., Evans, S. C., Lin, S., Liang, H., Liang, L., et al. (2017) · Scientific Reports · doi:10.1038/srep46426 · Cited by 87
Cited by
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
TLR8 escapes X chromosome inactivation in human monocytes and CD4+ T cells
Youness, A., Cenac, C., Faz-López, B., Grunenwald, S., Barrat, F. J., Chaumeil, J., Mejía, J. E., & Guéry, J.-C. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00544-5 · Cited by 58
Powers, N., Massena, C., Crouse, B., Smith, M., Hicks, L., Evans, J. T., Miller, S., Pravetoni, M., & Burkhart, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00347 · Cited by 15
Metadata
- Authors
- Dowling, D. J.
- Venue
- ImmunoHorizons
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-07-01
- Volume
- 2
- Issue
- 6
- Pages
- 185-197
- ISSN
- 2573-7732 (ISSN-L)
- OpenAlex
- W2811457913
- Cited by
- 160
- References
- 7
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.